Ontology highlight
ABSTRACT: Context
MK-5442 is an orally bioavailable calcium-sensing receptor antagonist that is hypothesized to stimulate bone formation by stimulating endogenous secretion of a pulse of PTH. Earlier clinical and preclinical studies demonstrated increased bone mineral density (BMD) after treatment.Objective
Our objective was to identify a dose of MK-5442 that produces osteoanabolic effects without excessive hypercalcemia.Design and setting
This was a randomized, double-blind, placebo-controlled, parallel-group trial of private or institutional practice.Participants and intervention
In total, 383 postmenopausal women with osteoporosis were administered daily oral MK-5442 (2.5, 5, 7.5, 10, or 15 mg) or placebo.Main outcome measures
Serum PTH and calcium, bone tu
SUBMITTER: Halse J
PROVIDER: S-EPMC5393499 | biostudies-literature | 2014 Nov
REPOSITORIES: biostudies-literature